


Amendments to the Claims

1. (Original) A compound of the formula (I):



wherein

ring A is an azetidine ring which may have further substituent(s),

X is oxygen, sulfur or nitrogen which may have substituent(s),

R¹, R², R³ and R⁴ are each independently, hydrogen, a hydrocarbon group which may have substituent(s), -SO₂R⁵ or a heterocyclic ring which may have substituent(s),

R⁵ is a hydrocarbon group which may have substituent(s),


R¹ and R², and R³ and R⁴ may be taken together to form an N-containing heterocyclic ring group which may have further substituent(s),

a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof.

2. (Original) The compound according to claim 1, wherein X is oxygen.

3. (Original) The compound according to claim 1, wherein R¹, R², R³ and R⁴ are each independently, hydrogen, a hydrocarbon group which may have substituent(s), or a heterocyclic ring group which may have substituent(s).

4. (Currently amended) The compound according to claim 1, which is a compound of the formula (I-1):



wherein

R¹ and R² are each independently hydrogen, a hydrocarbon group which may have substituent(s), -SO₂R⁵ or a heterocyclic ring group which may have substituent(s),

R⁵ is a hydrocarbon group which may have substituent(s),

R¹ and R² are taken together with the adjacent nitrogen atom to form an N-containing heterocyclic ring group which may have substituent(s),

R¹¹ is any arbitrary substituent(s), and

n is 0 or an ~~integer~~ integer of 1-5, with the proviso that when n is 2 or more, the plural R¹¹s may be the same or different.

5. (Currently amended) The compound according to claim 1-~~or~~4 wherein R¹ and R² are taken together with the adjacent nitrogen atom to form an N-containing heterocyclic ring group which may further have substituent(s).

6. (Currently amended) The compound according to claim 1-~~or~~5, wherein the N-containing heterocyclic ring group is a piperidine, piperazine, or indoline ring.

7. (Currently amended) The compound according to claim 1-~~or~~4, wherein R¹ is a benzene ring which may have substituent(s).

8. (Original) The compound according to claim 1, which is selected from the group consisting of N-(3,5-dichlorophenyl)-3-(4-phenylpiperidin-1-yl)azetidine-1-carboxamide, 3-(2,3-dihydro-1H-indol-1-yl)-N-[3-(trifluoromethyl)phenyl]azetidine-1-carboxamide, N-(3,5-dichlorophenyl)-3-(2,3-dihydro-1H-indol-1-yl)azetidine-1-carboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-3-(2,3-dihydro-1H-indol-1-yl)azetidine-1-carboxamide, 3-(2,3-dihydro-1H-indol-1-yl)-N-(3-phenoxyphenyl)azetidine-1-carboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-3-[methyl(phenyl)amino]azetidine-1-carboxamide and N-[3,5-bis(trifluoromethyl)phenyl]-3-[ethyl(phenyl)amino]azetidine-1-carboxamide.

9. (Currently amended) A pharmaceutical composition comprising the compound of the formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof described in claim 1, together with a pharmaceutically acceptable carrier.

10. (Original) The pharmaceutical composition according to claim 9, which is an S1P receptor antagonist.

11. (Original) The pharmaceutical composition according to claim 10, which is an EDG-5 antagonist.

12. (Original) The pharmaceutical composition according to claim 9, which is a preventive and/or therapeutic agent for the diseases induced by blood vessel contraction.

13. (Original) The pharmaceutical composition according to claim 12, wherein the diseases induced by blood vessel contraction include cerebrovascular spasms disease, hypertension, pulmonary hypertension, myocardial infarction, angina pectoris and portal hypertension.

14. (Original) The pharmaceutical composition according to claim 9, which is a preventive and/or therapeutic agent for respiratory diseases.

15. (Original) The pharmaceutical composition according to claim 14, wherein the respiratory diseases include bronchial asthma and chronic obstructive pulmonary disease.

16. (Original) A medicament comprising a combination of the compound of the formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof described in claim 1, and one or more member(s) selected from the group consisting of a calcium antagonist, a thrombolytic agent, a thromboxane synthase inhibitor, an endothelin antagonist, an antioxidant agent, a radical scavenger, a poly-ADP ribose polymerase inhibitor, an astrocyte-function improvement agent, a vasodilating agent and an Rho kinase inhibitor.

17. (Currently amended) A method for the prevention and/or treatment of an EDG-5 mediated disease in a mammal, characterized by administering to a mammal an

effective dose of the compound of the formula (I), a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof.

18. (Currently amended) ~~Use of the compound of the formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof described in claim 1,~~
A method for the manufacture of the preventive and/or therapeutic agent for EDG-5 mediated diseases, which comprises mixing the compound of the formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof as described in claim 1 with a pharmaceutically acceptable carrier.

19. (Original) A method for the preparation of the compound of the formula (I), a salt thereof, an N-oxide thereof or a prodrug thereof described in claim 1.